Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 7.063
Filter
1.
BMC Infect Dis ; 24(1): 552, 2024 Jun 03.
Article in English | MEDLINE | ID: mdl-38831406

ABSTRACT

BACKGROUND: Persistent infections with high-risk human papillomavirus (hrHPV) can cause cervical squamous intraepithelial lesions (SIL) that may progress to cancer. The cervicovaginal microbiome (CVM) correlates with SIL, but the temporal composition of the CVM after hrHPV infections has not been fully clarified. METHODS: To determine the association between the CVM composition and infection outcome, we applied high-resolution microbiome profiling using the circular probe-based RNA sequencing technology on a longitudinal cohort of cervical smears obtained from 141 hrHPV DNA-positive women with normal cytology at first visit, of whom 51 were diagnosed by cytology with SIL six months later. RESULTS: Here we show that women with a microbial community characterized by low diversity and high Lactobacillus crispatus abundance at both visits exhibit low risk to SIL development, while women with a microbial community characterized by high diversity and Lactobacillus depletion at first visit have a higher risk of developing SIL. At the level of individual species, we observed that a high abundance for Gardnerella vaginalis and Atopobium vaginae at both visits associate with SIL outcomes. These species together with Dialister micraerophilus showed a moderate discriminatory power for hrHPV infection progression. CONCLUSIONS: Our results suggest that the CVM can potentially be used as a biomarker for cervical disease and SIL development after hrHPV infection diagnosis with implications on cervical cancer prevention strategies and treatment of SIL.


Subject(s)
Cervix Uteri , Microbiota , Papillomavirus Infections , Vagina , Humans , Female , Longitudinal Studies , Vagina/microbiology , Vagina/virology , Papillomavirus Infections/virology , Papillomavirus Infections/microbiology , Adult , Cervix Uteri/microbiology , Cervix Uteri/virology , Middle Aged , Papillomaviridae/genetics , Papillomaviridae/isolation & purification , Papillomaviridae/classification , Young Adult , Uterine Cervical Neoplasms/virology , Uterine Cervical Neoplasms/microbiology , Vaginal Smears
2.
Infect Dis Clin North Am ; 38(2): 241-253, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38729665

ABSTRACT

This article discusses the urinary microbiome in relation to urinary tract infection (UTI) in women. It makes biologic sense that the microbiota of different niches (bladder, vagina, and gut) interact with each other in health, as well as during a UTI event; however, these relationships remain poorly understood. Future research should close knowledge gaps regarding the interactions between the urinary microbiota and the host, amongst the microbiota of adjacent niches, and between the microbes within the same microbiota. The new knowledge should result in improved UTI treatment in the age of antibiotic stewardship.


Subject(s)
Microbiota , Urinary Tract Infections , Humans , Urinary Tract Infections/diagnosis , Urinary Tract Infections/microbiology , Urinary Tract Infections/drug therapy , Female , Adult , Anti-Bacterial Agents/therapeutic use , Urinary Tract/microbiology , Vagina/microbiology , Urinary Bladder/microbiology
3.
Clin Perinatol ; 51(2): 425-439, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38705650

ABSTRACT

This review illuminates the complex interplay between various maternal microbiomes and their influence on preterm birth (PTB), a driving and persistent contributor to neonatal morbidity and mortality. Here, we examine the dynamics of oral, gastrointestinal (gut), placental, and vaginal microbiomes, dissecting their roles in the pathogenesis of PTB. Importantly, focusing on the vaginal microbiome and PTB, the review highlights (1) a protective role of Lactobacillus species; (2) an increased risk with select anaerobes; and (3) the influence of social health determinants on the composition of vaginal microbial communities.


Subject(s)
Gastrointestinal Microbiome , Microbiota , Placenta , Premature Birth , Vagina , Humans , Female , Pregnancy , Premature Birth/microbiology , Premature Birth/epidemiology , Vagina/microbiology , Infant, Newborn , Placenta/microbiology , Gastrointestinal Microbiome/physiology , Lactobacillus , Mouth/microbiology
4.
PLoS One ; 19(5): e0303449, 2024.
Article in English | MEDLINE | ID: mdl-38768097

ABSTRACT

Candida albicans (C. albicans) can behave as a commensal yeast colonizing the vaginal mucosa, and in this condition is tolerated by the epithelium. When the epithelial tolerance breaks down, due to C. albicans overgrowth and hyphae formation, the generated inflammatory response and cell damage lead to vulvovaginal candidiasis (VVC) symptoms. Here, we focused on the induction of mitochondrial reactive oxygen species (mtROS) in vaginal epithelial cells after C. albicans infection and the involvement of fungal burden, morphogenesis and candidalysin (CL) production in such induction. Bioluminescent (BLI) C. albicans, C. albicans PCA-2 and C. albicans 529L strains were employed in an in vitro infection model including reconstituted vaginal epithelium cells (RVE), produced starting from A-431 cell line. The production of mtROS was kinetically measured by using MitoSOX™ Red probe. The potency of C. albicans to induced cell damage to RVE and C. albicans proliferation have also been evaluated. C. albicans induces a rapid mtROS release from vaginal epithelial cells, in parallel with an increase of the fungal load and hyphal formation. Under the same experimental conditions, the 529L C. albicans strain, known to be defective in CL production, induced a minor mtROS release showing the key role of CL in causing epithelial mithocondrial activation. C. albicans PCA-2, unable to form hyphae, induced comparable but slower mtROS production as compared to BLI C. albicans yeasts. By reducing mtROS through a ROS scavenger, an increased fungal burden was observed during RVE infection but not in fungal cultures grown on abiotic surface. Collectively, we conclude that CL, more than fungal load and hyphae formation, seems to play a key role in the rapid activation of mtROS by epithelial cells and in the induction of cell-damage and that mtROS are key elements in the vaginal epithelial cells response to C. albicans.


Subject(s)
Candida albicans , Candidiasis, Vulvovaginal , Epithelial Cells , Fungal Proteins , Mitochondria , Reactive Oxygen Species , Vagina , Candida albicans/metabolism , Candida albicans/physiology , Female , Humans , Mitochondria/metabolism , Vagina/microbiology , Reactive Oxygen Species/metabolism , Epithelial Cells/microbiology , Epithelial Cells/metabolism , Fungal Proteins/metabolism , Candidiasis, Vulvovaginal/microbiology , Hyphae/metabolism , Hyphae/growth & development , Cell Line
5.
Gut Microbes ; 16(1): 2351503, 2024.
Article in English | MEDLINE | ID: mdl-38748594

ABSTRACT

C-section is crucial in reducing maternal and neonatal mortality when medically indicated, but one of its side effects could be the disruption of vertical transmission of maternal-infant microbiota during delivery, potentially leading to gut dysbiosis and increased disease risks in C-section infants. To address such dysbiosis, it seems reasonable to supplement "what is missing" during C-section procedure. This idea has prompted several clinical trials, including proof-of-concept, investigating interventions like vaginal microbial seeding, oral administration of maternal vaginal microbes and even oral administration of maternal fecal materials. Hereby, we have summarized these trials to help understand the current state of these researches, highlighting the predominantly pilot nature of most of these studies and emphasizing the need for well-designed studies with larger sample to guide evidence-based medicine in the future.


C-section is associated with gut dysbiosis in CS infants and increased disease risks from childhood to adulthood.Apart from using traditional probiotics to restore CS-related dysbiosis, a new research direction is to investigate the potential of mimicking natural inoculation process would alleviate infant gut dysbiosis.Several small-scale studies have shown that transplanting maternal vaginal or even fecal microbiota might restore CS-related infant dysbiosis. Controversy remains regarding the clinical applicability, safety, efficacy and mechanisms of these approaches.


Subject(s)
Cesarean Section , Dysbiosis , Fecal Microbiota Transplantation , Gastrointestinal Microbiome , Humans , Dysbiosis/microbiology , Female , Cesarean Section/adverse effects , Pregnancy , Infant, Newborn , Vagina/microbiology , Infant
6.
J Int Med Res ; 52(5): 3000605241239021, 2024 May.
Article in English | MEDLINE | ID: mdl-38726878

ABSTRACT

OBJECTIVE: Recurrent bacterial vaginosis (RBV) after antibiotic treatment has relapse rates of 35% within 3 months and 60% within 12 months. A medical device containing polycarbophil, lauryl glucoside, and glycerides (PLGG) inhibits bacterial growth and has mucoadhesive properties. This study examined the efficacy of the device in women with RBV. METHODS: This post-market clinical follow-up study comprised two phases. The first phase was an interventional, open-label, non-controlled, multicenter study enrolling 56 women. The second phase was an observational 10-month follow-up without treatment. RESULTS: After three cycles of PLGG treatment, recurrence was identified in 8 of 54 evaluable patients (14.81%). A positive effect on lactobacilli in the vaginal secretions was observed in 26 of 39 patients (66.67%). Among 35 patients observed after stopping PLGG treatment, one case of RBV (2.86%) was observed after 4 months, and an additional six cases (17.14%) were observed after 10 ± 2 months. Therefore, no recurrence was evidenced in 12 subjects (34.28%) at the end of the study. CONCLUSION: The use of PLGG vaginal ovules in the treatment of BV reduces the rate of recurrence and apparently produces a positive effect on the vaginal microbiota.


Subject(s)
Recurrence , Vagina , Vaginosis, Bacterial , Humans , Female , Vaginosis, Bacterial/drug therapy , Vaginosis, Bacterial/microbiology , Adult , Follow-Up Studies , Vagina/microbiology , Middle Aged , Treatment Outcome , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Lactobacillus/isolation & purification , Administration, Intravaginal , Young Adult
7.
Sex Transm Dis ; 51(6): 437-440, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38733973

ABSTRACT

OBJECTIVES: Live biotherapeutic products (LBPs) containing vaginal Lactobacillus crispatus are promising adjuvant treatments to prevent recurrent bacterial vaginosis (BV) but may depend on the success of initial antibiotic treatment. METHODS: A post hoc analysis of data collected during the phase 2b LACTIN-V randomized control trial (L. crispatus CTV-05) explored the impact of clinical BV cure defined as Amsel criteria 0 of 3 (excluding pH, per 2019 Food and Drug Administration guidance) 2 days after completion of treatment with vaginal metronidazole gel on the effectiveness of an 11-week LACTIN-V dosing regimen to prevent BV recurrence by 12 and 24 weeks. RESULTS: At enrollment, 88% of participants had achieved postantibiotic clinical BV cure. The effect of LACTIN-V on BV recurrence compared with placebo differed by initial clinical BV cure status. The LACTIN-V to placebo risk ratio of BV recurrence by 12 weeks was 0.56 (95% confidence interval, 0.35-0.77) among participants with initial clinical BV cure after metronidazole treatment and 1.34 (95% confidence interval, 0.47-2.23) among participants without postantibiotic clinical BV cure. Among women receiving LACTIN-V, those who had achieved postantibiotic clinical BV cure at enrollment reached higher levels of detectable L. crispatus CTV-05 compared with women failing to achieve postantibiotic clinical BV cure. CONCLUSIONS: LACTIN-V seems to only decrease BV recurrence in women with clinical cure of BV after initial antibiotic treatment. Future trials of LBPs should consider limiting enrollment to these women.


Subject(s)
Anti-Bacterial Agents , Lactobacillus crispatus , Metronidazole , Probiotics , Vaginosis, Bacterial , Humans , Female , Vaginosis, Bacterial/drug therapy , Vaginosis, Bacterial/prevention & control , Vaginosis, Bacterial/microbiology , Metronidazole/administration & dosage , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Adult , Lactobacillus crispatus/physiology , Probiotics/administration & dosage , Treatment Outcome , Recurrence , Secondary Prevention , Administration, Intravaginal , Young Adult , Vagina/microbiology , Double-Blind Method
9.
Sci Rep ; 14(1): 11183, 2024 05 16.
Article in English | MEDLINE | ID: mdl-38755259

ABSTRACT

Alterations in the vaginal microbiota, including both species composition and functional pathways, have been associated with HPV infection and progression of dysplasia to cervical cancer. To further explore this, shotgun metagenomic sequencing was used to taxonomically and functionally characterize the vaginal microbiota of women with and without cervical dysplasia. Women with histologically verified dysplasia (n = 177; low grade dysplasia (LSIL) n = 81, high-grade dysplasia (HSIL) n = 94, cancer n = 2) were compared with healthy controls recruited from the cervical screening programme (n = 177). Women with dysplasia had a higher vaginal microbial diversity, and higher abundances of Gardnerella vaginalis, Aerococcus christensenii, Peptoniphilus lacrimalis and Fannyhessea vaginae, while healthy controls had higher relative abundance of Lactobacillus crispatus. Genes involved in e.g. nucleotide biosynthesis and peptidoglycan biosynthesis were more abundant in women with dysplasia. Healthy controls showed higher abundance of genes important for e.g. amino acid biosynthesis, (especially L-lysine) and sugar degradation. These findings suggest that the microbiota may have a role in creating a pro-oncogenic environment in women with dysplasia. Its role and potential interactions with other components in the microenvironment deserve further exploration.


Subject(s)
Microbiota , Uterine Cervical Dysplasia , Vagina , Humans , Female , Vagina/microbiology , Adult , Uterine Cervical Dysplasia/microbiology , Uterine Cervical Dysplasia/pathology , Middle Aged , Case-Control Studies , Metagenomics/methods , Bacteria/genetics , Bacteria/classification
10.
J Obstet Gynaecol ; 44(1): 2349714, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38775009

ABSTRACT

BACKGROUND: The trend of increasing caesarean section (CS) rates brings up questions related to subfertility. Research regarding the influence of CS on assisted reproduction techniques (ART) is conflicting. A potential mechanism behind CS-induced subfertility is intra uterine fluid resulting from a caesarean scar defect or niche. The vaginal microbiome has been repeatedly connected to negative ART outcomes, but it is unknown if the microbiome is changed in relation to a niche. METHODS: This systematic review describes literature investigating the effect of a niche on live birth rates after assisted reproduction. Furthermore, studies investigating a difference in microbial composition in subfertile persons with a niche compared to no niche are evaluated. Pubmed, Embase and Web of Science were searched on March 2023 for comparative studies on both study questions. Inclusion criteria were i.e., English language, human-only studies, availability of the full article and presence of comparative pregnancy data on a niche. The quality of the included studies and their risk of bias were assessed using the Newcastle-Ottawa scale for cohort studies. The results were graphically displayed in a forest plot. RESULTS: Six retrospective cohort studies could be included on fertility outcomes, with a total of 1083 persons with a niche and 3987 without a niche. The overall direction of effect shows a negative impact of a niche on the live birth rate (pooled aOR 0.58, 95% CI 0.48-0.69) with low-grade evidence. Three studies comparing the microbiome between persons with and without a CS could be identified. CONCLUSION: There is low-grade evidence to conclude that the presence of a niche reduces live birth rates when compared to persons without a niche. The theory that a caesarean has a negative impact on pregnancy outcomes because of dysbiosis promoted by the niche is interesting, but there is no sufficient literature about this.


The increasing number of caesarean deliveries has raised concerns about how it might affect a woman's ability to get pregnant afterwards. Some studies suggest that having a caesarean section (CS) could make it harder to conceive, particularly through in vitro fertilisation (IVF). The reason could be the scar or niche from a previous caesarean. This niche can cause fluid inside the uterus. We also know that the mix of bacteria in the vagina, called the vaginal microbiome, can affect a woman's chances of getting pregnant, especially with treatments like IVF. But we are not sure if having a caesarean affects the vaginal microbiome.To understand this better, van den Tweel's team looked at studies on whether having a niche from a caesarean affects a woman's chance of having a baby through IVF. They also looked at studies comparing the bacteria in the vagina of women who have had a caesarean with those who have not. They found that having a caesarean niche makes it harder for a woman to have a baby through IVF. However, the evidence from these studies is not very strong. We still do not know enough about whether having a caesarean niche affects the bacteria in the vagina.


Subject(s)
Cesarean Section , Cicatrix , Humans , Female , Cicatrix/etiology , Cesarean Section/adverse effects , Cesarean Section/statistics & numerical data , Pregnancy , Reproductive Techniques, Assisted/adverse effects , Vagina/microbiology , Microbiota , Infertility, Female/etiology , Infertility, Female/microbiology , Live Birth , Fertility , Adult , Birth Rate
11.
Article in English | MEDLINE | ID: mdl-38765512

ABSTRACT

• The balanced vaginal microbiome is the main factor defending the vaginal environment against infections. Lactobacilli play a key role in this regard, maintaining the vaginal pH within the normal range (3.8 to 4.5). •Hormonal and immune adaptations resulting from pregnancy influence changes in the vaginal microbiome during pregnancy. •An altered vaginal microbiome predisposes to human immunodeficiency virus (HIV) infection. •Bacterial vaginosis is the main clinical expression of an imbalanced vaginal microbiome. •Vulvovaginal candidiasis depends more on the host's conditions than on the etiological agent. •Trichomonas vaginalis is a protozoan transmitted during sexual intercourse. •The use of probiotics is not approved for use in pregnant women.


Subject(s)
Pregnancy Complications, Infectious , Vulvovaginitis , Humans , Female , Pregnancy , Vulvovaginitis/microbiology , Microbiota , Vagina/microbiology , Vaginosis, Bacterial
12.
Appl Microbiol Biotechnol ; 108(1): 339, 2024 May 21.
Article in English | MEDLINE | ID: mdl-38771520

ABSTRACT

The human microbiome, a diverse ecosystem of microorganisms within the body, plays pivotal roles in health and disease. This review explores site-specific microbiomes, their role in maintaining health, and strategies for their upkeep, focusing on oral, lung, vaginal, skin, and gut microbiota, and their systemic connections. Understanding the intricate relationships between these microbial communities is crucial for unraveling mechanisms underlying human health. Recent research highlights bidirectional communication between the gut and distant microbiome sites, influencing immune function, metabolism, and disease susceptibility. Alterations in one microbiome can impact others, emphasizing their interconnectedness and collective influence on human physiology. The therapeutic potential of gut microbiota in modulating distant microbiomes offers promising avenues for interventions targeting various disorders. Through interdisciplinary collaboration and technological advancements, we can harness the power of the microbiome to revolutionize healthcare, emphasizing microbiome-centric approaches to promote holistic well-being while identifying areas for future research.


Subject(s)
Gastrointestinal Microbiome , Humans , Microbiota , Skin/microbiology , Vagina/microbiology , Lung/microbiology , Mouth/microbiology , Female , Gastrointestinal Tract/microbiology
13.
J Appl Microbiol ; 135(5)2024 May 01.
Article in English | MEDLINE | ID: mdl-38755019

ABSTRACT

AIM: The present study is a single-centre, randomized, controlled clinical trial aimed to evaluate the effectiveness of the probiotic Lacticaseibacillus rhamnosus TOM 22.8 (DSM 33500) strain, orally administrated, to treat vaginal dysbiosis. METHODS AND RESULTS: Overall, 80 women, with signs and symptoms of vaginal dysbiosis, were enrolled and allocated to the treatment group (A, n=60), who took 1 capsule of the probiotic strain for 10 consecutive days, or the non-treatment group (B, n=20), who did not receive any treatment. Clinical (vaginal signs and symptoms; pH of the vaginal fluid; Amsel criteria; Nugent score; Lactobacillary grade) and microbiological examinations were performed at baseline (T0), 10 days (T1), and 30 (T2) days after the oral administration of the probiotic TOM 22.8 strain. The latter resulted in a restoration of the physiological pH, accompanied by remission or attenuation of clinical signs and symptoms as well as the improvement of the quality of life (QoL). Microbiological data revealed a significant reduction of potentially pathogenic bacteria. CONCLUSION: The administration of the L. rhamnosus TOM 22.8 probiotic strain could be proposed as an effective strategy for the treatment of vaginal dysbiosis.


Subject(s)
Dysbiosis , Lacticaseibacillus rhamnosus , Probiotics , Vagina , Female , Humans , Probiotics/administration & dosage , Probiotics/therapeutic use , Dysbiosis/microbiology , Vagina/microbiology , Adult , Middle Aged , Young Adult , Quality of Life , Lactobacillus , Vaginosis, Bacterial/microbiology , Vaginosis, Bacterial/drug therapy
14.
Rev Int Androl ; 22(1): 38-43, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38735876

ABSTRACT

It is estimated that microorganisms colonize 90% of the body surface. In some tracts, such as the genitourinary tract, the microbiota varies throughout life, influenced by hormonal stimulation and sexual practices. This study evaluated the semen differences and presence of Lactobacillus crispatus, Lactobacillus iners, Gardnerella vaginalis and Atopobium vaginae in semen samples from patients with symptoms of chronic prostatitis and men asymptomatic for urogenital infections. Fifty-three semen samples were included: 22 samples from men with symptoms of chronic prostatitis and 31 asymptomatic men (control group). In addition to the presence of L. crispatus, L. iners, G. vaginalis and A. vaginae, semen parameters, total antioxidant capacity of seminal plasma, prostatic antigen and some proinflammatory cytokines were evaluated in each semen sample. Volunteers with symptoms of chronic prostatitis presented a lower percentage of sperm morphology (4.3% vs. control group 6.0%, p = 0.004); in the semen samples of volunteers in the group asymptomatic for urogenital infections, microorganisms associated with the vaginal microbiota were detected more frequently. The presence of bacteria in the vaginal microbiota can also benefit male reproductive health, which undergoes various modifications related to lifestyle habits that are susceptible to modification. Microorganisms associated with the vaginal microbiota, such as L. crispatus, L. iners, G. vaginalis and A. vaginae, may have a protective role against the development of male genitourinary diseases such as prostatitis.


Subject(s)
Coitus , Microbiota , Prostatitis , Semen , Humans , Male , Prostatitis/microbiology , Semen/microbiology , Adult , Microbiota/physiology , Gardnerella vaginalis/isolation & purification , Lactobacillus/isolation & purification , Vagina/microbiology , Middle Aged , Actinobacteria/isolation & purification , Female , Young Adult , Chronic Disease , Case-Control Studies , Semen Analysis , Cytokines/metabolism , Cytokines/analysis
15.
Sci Rep ; 14(1): 11798, 2024 05 23.
Article in English | MEDLINE | ID: mdl-38782975

ABSTRACT

Using pooled vaginal microbiota data from pregnancy cohorts (N = 683 participants) in the Environmental influences on Child Health Outcomes (ECHO) Program, we analyzed 16S rRNA gene amplicon sequences to identify clinical and demographic host factors that associate with vaginal microbiota structure in pregnancy both within and across diverse cohorts. Using PERMANOVA models, we assessed factors associated with vaginal community structure in pregnancy, examined whether host factors were conserved across populations, and tested the independent and combined effects of host factors on vaginal community state types (CSTs) using multinomial logistic regression models. Demographic and social factors explained a larger amount of variation in the vaginal microbiome in pregnancy than clinical factors. After adjustment, lower education, rather than self-identified race, remained a robust predictor of L. iners dominant (CST III) and diverse (CST IV) (OR = 8.44, 95% CI = 4.06-17.6 and OR = 4.18, 95% CI = 1.88-9.26, respectively). In random forest models, we identified specific taxonomic features of host factors, particularly urogenital pathogens associated with pregnancy complications (Aerococcus christensenii and Gardnerella spp.) among other facultative anaerobes and key markers of community instability (L. iners). Sociodemographic factors were robustly associated with vaginal microbiota structure in pregnancy and should be considered as sources of variation in human microbiome studies.


Subject(s)
Microbiota , RNA, Ribosomal, 16S , Vagina , Humans , Female , Pregnancy , Vagina/microbiology , Microbiota/genetics , Adult , RNA, Ribosomal, 16S/genetics , Cohort Studies , Young Adult
16.
Comp Immunol Microbiol Infect Dis ; 109: 102188, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38691873

ABSTRACT

This study aimed to evaluate the bacterial burden and perform molecular characterization of Coxiella burnetii during shedding in pregnant (vaginal, mucus and feces) and postpartum (vaginal mucus, feces and milk) ewes from Saint Kitts. Positive IS1111 DNA (n=250) for C. burnetii samples from pregnant (n=87) and postpartum (n=74) Barbados Blackbelly ewes in a previous investigation were used for this study. Vaginal mucus (n=118), feces (n=100), and milk (n=32) positive IS1111 C. burnetii-DNA were analysed by real time qPCR (icd gene). For molecular characterization of C. burnetii, selected (n=10) IS1111 qPCR positive samples were sequenced for fragments of the IS1111 element and the 16 S rRNA gene. nBLAST, phylogenetic and haplotype analyses were performed. Vaginal mucus, feces and milk had estimated equal amounts of bacterial DNA (icd copies), and super spreaders were detected within the fecal samples. C. burnetii haplotypes had moderate to high diversity, were ubiquitous worldwide and similar to previously described in ruminants and ticks and humans.


Subject(s)
Coxiella burnetii , DNA, Bacterial , Feces , Milk , Phylogeny , Postpartum Period , Q Fever , Sheep Diseases , Vagina , Animals , Coxiella burnetii/genetics , Coxiella burnetii/isolation & purification , Female , Q Fever/veterinary , Q Fever/microbiology , Pregnancy , Feces/microbiology , Sheep/microbiology , Sheep Diseases/microbiology , Vagina/microbiology , DNA, Bacterial/genetics , Milk/microbiology , Bacterial Shedding , Bacterial Load , RNA, Ribosomal, 16S/genetics , Haplotypes
17.
Gut Microbes ; 16(1): 2353394, 2024.
Article in English | MEDLINE | ID: mdl-38743047

ABSTRACT

Exposing C-section infants to the maternal vaginal microbiome, coined "vaginal seeding", partially restores microbial colonization. However, whether vaginal seeding decreases metabolic disease risk is unknown. Therefore, we assessed the effect of vaginal seeding of human infants on adiposity in a murine model. Germ-free mice were colonized with transitional stool from human infants who received vaginal seeding or control (placebo) seeding in a double-blind randomized trial. There was a reduction in intraabdominal adipose tissue (IAAT) volume in male mice that received stool from vaginally seeded infants compared to control infants. Higher levels of isoleucine and lower levels of nucleic acid metabolites were observed in controls and correlated with increased IAAT. This suggests that early changes in the gut microbiome and metabolome caused by vaginal seeding have a positive impact on metabolic health.


Subject(s)
Adiposity , Fecal Microbiota Transplantation , Feces , Gastrointestinal Microbiome , Vagina , Animals , Humans , Female , Mice , Male , Vagina/microbiology , Feces/microbiology , Feces/chemistry , Double-Blind Method , Intra-Abdominal Fat/metabolism , Infant , Infant, Newborn
18.
BMC Vet Res ; 20(1): 200, 2024 May 15.
Article in English | MEDLINE | ID: mdl-38745199

ABSTRACT

BACKGROUND: In dairy cattle, mastitis causes high financial losses and impairs animal well-being. Genetic selection is used to breed cows with reduced mastitis susceptibility. Techniques such as milk cell flow cytometry may improve early mastitis diagnosis. In a highly standardized in vivo infection model, 36 half-sib cows were selected for divergent paternal Bos taurus chromosome 18 haplotypes (Q vs. q) and challenged with Escherichia coli for 24 h or Staphylococcus aureus for 96 h, after which the samples were analyzed at 12 h intervals. Vaginal temperature (VT) was recorded every three minutes. The objective of this study was to compare the differential milk cell count (DMCC), milk parameters (fat %, protein %, lactose %, pH) and VT between favorable (Q) and unfavorable (q) haplotype cows using Bayesian models to evaluate their potential as improved early indicators of differential susceptibility to mastitis. RESULTS: After S. aureus challenge, compared to the Q half-sibship cows, the milk of the q cows exhibited higher PMN levels according to the DMCC (24 h, p < 0.001), a higher SCC (24 h, p < 0.01 and 36 h, p < 0.05), large cells (24 h, p < 0.05) and more dead (36 h, p < 0.001) and live cells (24 h, p < 0.01). The protein % was greater in Q milk than in q milk at 0 h (p = 0.025). In the S. aureus group, Q cows had a greater protein % (60 h, p = 0.048) and fat % (84 h, p = 0.022) than q cows. Initially, the greater VT of S. aureus-challenged q cows (0 and 12-24 h, p < 0.05) reversed to a lower VT in q cows than in Q cows (48-60 h, p < 0.05). Additionally, the following findings emphasized the validity of the model: in the S. aureus group all DMCC subpopulations (24 h-96 h, p < 0.001) and in the E. coli group nearly all DMCC subpopulations (12 h-24 h, p < 0.001) were higher in challenged quarters than in unchallenged quarters. The lactose % was lower in the milk samples of E. coli-challenged quarters than in those of S. aureus-challenged quarters (24 h, p < 0.001). Between 12 and 18 h, the VT was greater in cows challenged with E. coli than in those challenged with S. aureus (3-h interval approach, p < 0.001). CONCLUSION: This in vivo infection model confirmed specific differences between Q and q cows with respect to the DMCC, milk component analysis results and VT results after S. aureus inoculation but not after E. coli challenge. However, compared with conventional milk cell analysis monitoring, e.g., the global SCC, the DMCC analysis did not provide refined phenotyping of the pathogen response.


Subject(s)
Escherichia coli Infections , Escherichia coli , Haplotypes , Mastitis, Bovine , Milk , Staphylococcal Infections , Staphylococcus aureus , Animals , Cattle , Milk/microbiology , Milk/cytology , Female , Mastitis, Bovine/microbiology , Staphylococcus aureus/physiology , Escherichia coli Infections/veterinary , Escherichia coli Infections/microbiology , Staphylococcal Infections/veterinary , Staphylococcal Infections/microbiology , Cell Count/veterinary , Body Temperature , Vagina/microbiology
19.
J Reprod Immunol ; 163: 104251, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38718429

ABSTRACT

Recurrent pregnancy loss (RPL) is a troubling condition that affects couples worldwide. Despite extensive research efforts, many RPL cases remain unexplained, highlighting the need for novel approaches to unravel its underlying mechanisms. Recent advances in microbiome research have shed light on the potential role of the microbiome in reproductive health and outcomes. Based on a systematic literature research, this review aims to comprehensively explore the current understanding of the microbiome's involvement in RPL, focusing on the vaginal, endometrial, and gut microbiomes. Evidence from the available studies is examined to explain the relationship between the microbiome and RPL. Furthermore, we discuss the diagnostic potential of the microbiome, therapeutic interventions, and future directions in microbiome research for RPL. Understanding the complex interactions between the microbiome and reproductive health holds promise for developing targeted interventions to help patients today diagnosed as unexplained.


Subject(s)
Abortion, Habitual , Microbiota , Humans , Abortion, Habitual/microbiology , Abortion, Habitual/immunology , Abortion, Habitual/diagnosis , Female , Pregnancy , Microbiota/immunology , Gastrointestinal Microbiome/immunology , Endometrium/microbiology , Endometrium/immunology , Endometrium/pathology , Vagina/microbiology , Vagina/immunology
20.
Sci Rep ; 14(1): 12226, 2024 05 28.
Article in English | MEDLINE | ID: mdl-38806600

ABSTRACT

The human microbiome contains genetic information that regulates metabolic processes in response to host health and disease. While acidic vaginal pH is maintained in normal conditions, the pH level increases in infectious vaginitis. We propose that this change in the vaginal environment triggers the biosynthesis of anti-vaginitis metabolites. Gene expression levels of Chryseobacterium gleum, a vaginal symbiotic bacterium, were found to be affected by pH changes. The distinctive difference in the metabolic profiles between two C. gleum cultures incubated under acidic and neutral pH conditions was suggested to be an anti-vaginitis molecule, which was identified as phenylacetic acid (PAA) by spectroscopic data analysis. The antimicrobial activity of PAA was evaluated in vitro, showing greater toxicity toward Gardnerella vaginalis and Candida albicans, two major vaginal pathogens, relative to commensal Lactobacillus spp. The activation of myeloperoxidase, prostaglandin E2, and nuclear factor-κB, and the expression of cyclooxygenase-2 were reduced by an intravaginal administration of PAA in the vaginitis mouse model. In addition, PAA displayed the downregulation of mast cell activation. Therefore, PAA was suggested to be a messenger molecule that mediates interactions between the human microbiome and vaginal health.


Subject(s)
Chryseobacterium , Phenylacetates , Vagina , Female , Animals , Phenylacetates/metabolism , Phenylacetates/pharmacology , Vagina/microbiology , Mice , Humans , Chryseobacterium/metabolism , Candida albicans/metabolism , Candida albicans/drug effects , Symbiosis , Hydrogen-Ion Concentration , Gardnerella vaginalis/metabolism , Gardnerella vaginalis/drug effects , Disease Models, Animal , Vaginitis/microbiology , Vaginitis/metabolism , Vaginitis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...